AnaptysBio, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 163.62 million compared to USD 128.72 million a year ago. Basic loss per share from continuing operations was USD 6.08 compared to USD 4.57 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.95 USD | -0.48% | +4.21% | +16.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.71% | 685M | |
+9.89% | 115B | |
+11.92% | 106B | |
-2.59% | 21.96B | |
-12.59% | 21.87B | |
-5.29% | 19.21B | |
-3.85% | 18.08B | |
-38.57% | 17.71B | |
+7.01% | 14.32B | |
+35.74% | 12.42B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023